Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations
1. New data from REZILIENT2 study on zipalertinib was shared. 2. Intracranial objective response rate was 31.3% in evaluated patients. 3. Safety profile was acceptable with no new safety signals reported. 4. CGEM stock rose 4.96% to $7.77 after data announcement. 5. Data to be presented at ESMO Congress 2025 in February.